Scott Gettinger
Overview
Explore the profile of Scott Gettinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
7641
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904562
Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its...
2.
Riely G, Wood D, Ettinger D, Aisner D, Akerley W, Bauman J, et al.
J Natl Compr Canc Netw
. 2024 May;
22(4):249-274.
PMID: 38754467
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance...
3.
Stevenson J, Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, et al.
J Natl Compr Canc Netw
. 2024 Mar;
22(2):72-81.
PMID: 38503043
Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States...
4.
Hu B, Wiesehofer M, de Miguel F, Liu Z, Chan L, Choi J, et al.
Cancer Res
. 2024 Feb;
84(8):1303-1319.
PMID: 38359163
Significance: Analysis of residual disease following tyrosine kinase inhibitor treatment identified heterogeneous and context-specific mechanisms of drug tolerance in lung cancer that could lead to the development of strategies to...
5.
Parra E, Zhang J, Duose D, Gonzalez-Kozlova E, Redman M, Chen H, et al.
Clin Cancer Res
. 2024 Jan;
30(8):1655-1668.
PMID: 38277235
Purpose: Identifying molecular and immune features to guide immune checkpoint inhibitor (ICI)-based regimens remains an unmet clinical need. Experimental Design: Tissue and longitudinal blood specimens from phase III trial S1400I...
6.
Stockhammer P, Grant M, Wurtz A, Foggetti G, Exposito F, Gu J, et al.
J Thorac Oncol
. 2023 Oct;
19(2):240-251.
PMID: 37806385
Introduction: Patients with metastatic EGFR-mutant NSCLC inevitably have disease progression while on tyrosine kinase inhibitor (TKI) therapy. Co-occurring tumor suppressor gene (TSG) alterations have been associated with poor outcomes, however,...
7.
Ettinger D, Wood D, Stevenson J, Aisner D, Akerley W, Bauman J, et al.
J Natl Compr Canc Netw
. 2023 Sep;
21(9):961-979.
PMID: 37673108
Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM)....
8.
Chiorazzi M, Martinek J, Krasnick B, Zheng Y, Robbins K, Qu R, et al.
J Immunother Cancer
. 2023 Jul;
11(7).
PMID: 37487666
Background: Interactions between immune and tumor cells are critical to determining cancer progression and response. In addition, preclinical prediction of immune-related drug efficacy is limited by interspecies differences between human...
9.
Kim S, Gettinger S
Hematol Oncol Clin North Am
. 2023 May;
37(3):557-573.
PMID: 37150586
Immunotherapy-based regimens are an established standard of care for the first-line treatment of driver-negative (EGFR/ALK/ROS WT) advanced non-small cell lung cancer. With multiple immune-based regimens approved in the first-line setting,...
10.
Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A, et al.
J Natl Compr Canc Netw
. 2023 Apr;
21(4):340-350.
PMID: 37015337
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known...